scholarly journals Impact of Gender, Partner Status, and Race on Locoregional Failure and Overall Survival in Head and Neck Cancer Patients in Three Radiation Therapy Oncology Group Trials

2011 ◽  
Vol 81 (3) ◽  
pp. e101-e109 ◽  
Author(s):  
Thomas J. Dilling ◽  
Kyounghwa Bae ◽  
Rebecca Paulus ◽  
Deborah Watkins-Bruner ◽  
Adam S. Garden ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Radiation Therapy Oncology Group ◽  
Oncology Group ◽  
Partner Status ◽  
Locoregional Failure

Evolution of the radiation therapy oncology group clinical trials for head and neck cancer

1996 ◽  
Vol 35 (3) ◽  
pp. 425-438 ◽  
Author(s):  
Karen K. Fu ◽  
Jay S. Cooper ◽  
Victor A. Marcial ◽  
George E. Laramore ◽  
Thomas F. Pajak ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Radiation Therapy Oncology Group ◽  
Oncology Group

scholarly journals Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Therapy Oncology Group 8502 “QUAD shot” regimen for incurable head and neck cancer

2020 ◽  
Author(s):  
Ryo Toya ◽  
Tetsuo Saito ◽  
Kohsei Yamaguchi ◽  
Tomohiko Matsuyama ◽  
Takahiro Watakabe ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tumor Response ◽  
Symptom Relief ◽  
Radiation Therapy Oncology Group ◽  
Oncology Group ◽  
Overall Response ◽  
Volumetric Modulated Arc Radiotherapy

Abstract Background: To review a single institutional experience of the Radiation Therapy Oncology Group (RTOG) 8502 “QUAD shot” regimen using volumetric modulated arc radiotherapy (VMAT) for incurable head and neck cancer (HNC).Methods: Thirty-four consecutive patients with HNC were treated with at least one cycle of the RTOG 8502 regimen. Treatment plans included the use of VMAT with 6 MV photons generated by a linear accelerator. Two daily fractions of 3.7 Gy were delivered with an interval of at least 6 h for 2 consecutive days, totaling 14.8 Gy over 4 fractions. This was repeated every 3–4 weeks for a total of three cycles. No concurrent systemic therapy was performed.Results: The number of completed cycles was 1 in 6 (18%) patients, 2 in 5 (15%), and 3 in 23 (68%). Tumor response was achieved in 29 (85%) patients and symptom relief in 20 (77%) of 26 patients. Overall response (tumor response or symptom relief) was achieved in 32 (94%) patients. All patients who received 2 or more treatment cycles achieved overall response. Median overall survival (OS) was 5.7 months. Multivariate analysis revealed that completion of all three treatment cycles was significantly associated with better OS (P = 0.002). Grade 2 toxicity was observed in four (12%) patients, but no acute Grade ≥3 or late toxicity was observed.Conclusions: The RTOG 8502 “QUAD shot” regimen using VMAT is effective for incurable HNC with highly reduced toxicity. Treatment with multiple cycles is recommended for better treatment response and/or survival.

Sign in / Sign up

Export Citation Format

Share Document